

31 October 2025

ASX ANNOUNCEMENT

2025 Q3 Activity Report and Appendix 4C

Financial Highlights¹

- Q3 FY25 revenue of \$7.2m, up 9% vs pcp; up 3% on a constant currency basis².
- YTD FY25 revenue of \$20.8m, up 6% excluding the one-off of \$0.7m in pcp; up 5% up on a constant currency basis.
- Q3 FY25 Underlying EBITDA of \$0.6m; break-even in pcp.
- YTD FY25 Underlying EBITDA³ of \$0.9m; \$0.2m in pcp.
- ARR⁴ of \$36.4m, up 24% vs pcp; up 12% on a constant currency basis.
- Debt of \$1.0m at 30 September 2025, down from \$1.3m at 30 June 2025.
- Cash of \$3.0m at 30 September 2025, up vs \$2.5m at 30 June 2025.

The Company Reconfirms Guidance for FY25:

- Revenue in the range \$27.5m to \$28.2m - up 4.0 to 6.6% on the prior year; and
- Underlying EBITDA in the range \$1.3m to \$1.6m - up vs \$0.5m in the prior year.

Operational Highlights

- Private-sector software contract wins: regained OMNI Hospital (Ecuador) after displacing a competitor, adding \$86,000 New Annual Recurring Revenue (NARR) via Mobitelemed; renewed and upgraded Grupo San Pablo (Peru) via KLD, adding \$88,000 NARR.
- RIMAB secured a one-year contract in Colombia with Oncolife to deliver high-complexity radiology services which is expected to contribute \$1.4m in NARR (services + software).
- Total Software NARR written in Q3 was \$417,000.
- Partner Programme expanded to 26 high-performing partners across 14 countries.
- IMEXHS Enterprise and IMEXHS Cloud finished the quarter with a total of 556 installations worldwide.

1 All financial information for FY25 in this announcement is preliminary, unaudited financial information and may be subject to adjustment following audit.

2 Constant currency basis assumes Q3 FY25 results are converted at the average foreign exchange rate for Q3 FY24 and YTD FY25 results are converted at the average foreign exchange rate for YTD FY24. This removes the impact of changes in currency rates and allows comparison of IMEXHS's underlying operating performance.

3 Underlying EBITDA excludes the impact of FX, share based payments and the impairment charge taken in 1H FY25.

4 Annualised Recurring Revenue (ARR) is the value of the monthly recurring contract revenue multiplied by twelve. Constant currency basis assumes the 30 Sept-25 ARR is converted at the 30 Sept-24 exchange rate.



Headquarters Australia

Sydney, Australia
Level 7, 32 Martin Place, SYDNEY 2000
Email: enquiries@imexhs.com.au

Headquarters Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
Email: soporte@imexhs.com

Headquarters USA

Doral, Florida.
8200 NW 41st, Suite No. 200-42, CP 33166
admin.usa@imexhs.com

For personal use only

IMEXHS Limited (ASX: IME) (“IMEXHS” or “the Company”) today provides its quarterly cash flow and activities summary for the period ended 30 September 2025. IMEXHS is an innovative provider of cloud-based medical imaging software and radiology services across 18 countries.

IMEXHS CEO Dr. German Arango said, “We expect that Q3 FY25 will be seen as a turning point for underlying EBITDA reflecting disciplined execution in Radiology Services and ongoing gains in software.

Over the next 12 months our priority is to strengthen and grow the software business across the region - expanding Aquila+ and our Enterprise cloud footprint - through a balanced mix of direct sales and high-performing partners. While a number of contracts expected to close in the quarter have slipped into Q4 FY25 and Q1 FY26 the pipeline of opportunities has continued to strengthen. Our partner channel has now delivered two consecutive strong quarters and is currently contributing the majority of Software NARR.

The company has improved its working capital position and aims to maintain that discipline. Margin expansion in Radiology has improved during the year. An important contributor to margin expansion has included AI-orchestrated call-centre workflows. Together the ongoing cost-saving programme and our revised pricing structure have further improved unit economics, with RIMAB continuing disciplined portfolio management, including the active exit of sub-scale or persistently late-paying contracts, thereby strengthening profitability across the business. We expect to similarly improve margins in software over the next six to nine months.

In Colombia, the policy backdrop remains fluid, but our contingency plan is working. We have tightened credit controls, re-phased collections and adjusted pricing to preserve cash conversion. As a result, working capital remains protected and liquidity stable despite intermittent sector-wide payment pressures.

Financial Summary

Q3 FY25 revenue of \$7.2m was up 9% vs pcp and up 3% on a constant currency basis

YTD FY25 revenue of \$20.8m was up 6% excluding the one-off of \$0.7m in pcp and up 5% up on a constant currency basis.

Q3 FY25 Underlying EBITDA was \$0.6m, up from break-even in pcp.

YTD FY25 Underlying EBITDA was \$0.9m, up from \$0.2m in pcp.

On 30 September 2025, IMEXHS held cash and cash equivalents of \$3.0m vs \$2.5m at 30 June 2025.

For personal use only



Headquarters Australia

Sydney, Australia
Level 7, 32 Martin Place, SYDNEY 2000
Email: enquiries@imexhs.com.au

Headquarters Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
Email: soporte@imexhs.com

Headquarters USA


Doral, Florida.
8200 NW 41st, Suite No. 200-42, CP 33166
admin.usa@imexhs.com

Annualised Recurring Revenue

ARR of \$36.4m as of 30 September 2025 was up 24% vs pcp and 12% up on a constant currency basis.

ARR of \$36.4m (\$32.8m as at 30 June 2025) consisted of \$24.7m from Radiology services (\$20.9m as at 30 June 2025) and \$11.7m from Software (\$11.9m as at 30 June 2025). ARR reduction in software for the quarter is due in part to an over-estimation at 30 June 2025 versus observed actuals together with a volume reduction elsewhere and offset by \$417,000 in NARR.

Chart 1 shows ARR at 30 September that is currently billing as well as ARR which is yet to commence billing.



Constant currency basis assumes that historic results are converted at the 30 Sept-25 exchange rate. This removes the impact of changes in currency rates and allows comparison of IMEXHS's underlying operating performance.

Cashflow

On 30 September 2025, IMEXHS held cash and cash equivalents of \$3.0m vs \$2.5m at 30 June 2025.

Q3 FY25 Net cash from operating activities was \$1.2m with cash receipts of \$7.9m in the quarter, up vs Q1 receipts of \$5.5m and Q2 receipts of \$5.6m. A strong quarter of cash collections together with tax credits allowed the company to pay down outstanding tax to nil.

YTD FY25 Net cash used in operating activities was \$0.3m vs \$0.8m in pcp.

Q3 FY25 Net cash used in investing activities was \$0.2m, with the company adding \$0.2m in capitalised software during the quarter. YTD FY25 Net cash used in investing activities was \$0.6m.

Q3 FY25 Net cash used in financing activities was \$0.4m in the quarter with the repayment of borrowings, reducing debt to \$1.0m at 30 September 2025.

YTD FY25 Net cash from financing activities was \$1.8m with net proceeds from the Capital Raising of \$2.4m partially offset by a net outflow in borrowings of \$0.6m.



Headquarters Australia

Sydney, Australia
Level 7, 32 Martin Place, SYDNEY 2000
Email: enquiries@imexhs.com.au

Headquarters Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
Email: soporte@imexhs.com

Headquarters USA

Doral, Florida.
8200 NW 41st, Suite No. 200-42, CP 33166
admin.usa@imexhs.com

Outlook and Guidance

The Company reconfirms guidance provided at the 1H FY25 Results on 29 August 2025.

Based on year-to-date performance and looking forward to our expectations for the Q4, the Company expects to achieve the following for FY25:

- Revenue in the range \$27.5m to \$28.2m - up 4.0 to 6.6% on the prior year; and
- Underlying EBITDA in the range \$1.3m to \$1.6m - up vs \$0.5m in the prior year.

Sales Update

In Q3 FY25 the Company processed 2.1m studies across its medical imaging platforms across 556 sites in 18 countries with ARR of \$11.7m at 30 September 2025.

IMEXHS Software

While several contracts expected to close in Q3 have slipped into Q4 the pipeline of opportunities has continued to strengthen. Good traction is being achieved in Mexico.

The Company regained OMNI Hospital in Ecuador - its flagship private hospital - after displacing a competitor, adding approximately \$86,000 in NARR through partner Mobitelemed. In Peru, the Company, via partner KLD, renewed and upgraded its contract with Grupo San Pablo, generating NARR of \$88,000. Grupo San Pablo remains a key IMEXHS client and one of Peru's leading private healthcare networks.

In Colombia, Fabilu – an institution based in Cali – renewed its contract for 36 months, covering two sites on a 100% cloud-based deployment, generating ARR of \$162,000.

Partner Programme

The partner network remained a core growth engine in Q3 FY25. We closed the quarter with 26 active partners across 14 countries, including 24 partners in 12 LatAm markets. Execution remained disciplined: we continued to onboard high-performing firms while offboarding under-performers to keep the programme tightly focused on quality.

New alliances strengthened both reach and capability. We signed a technology partnership with Bukeala in Argentina to enhance our digital-health offering, added two new partners in Colombia, and onboarded a Peru-based partner focused on the public sector.

For personal use only



Headquarters Australia

Sydney, Australia
Level 7, 32 Martin Place, SYDNEY 2000
Email: enquiries@imexhs.com.au

Headquarters Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
Email: soporte@imexhs.com

Headquarters USA

Doral, Florida.
8200 NW 41st, Suite No. 200-42, CP 33166
admin.usa@imexhs.com

Radiology Services

During the September quarter, RIMAB signed a one-year agreement to deliver high-complexity radiology services to Oncolife, a leading oncology provider with sites in Bogotá and two additional Colombian cities. The engagement will be supported by IMEXHS's RIS/PACS Enterprise platform, patient portal and selected AI diagnostic layers, and is expected to contribute approximately \$1.4m in NARR (combined services and software).

Building on Q2, in which we strengthened the cost-reduction programme—introducing AI-orchestrated call-centre workflows and piloting AI models to optimise X-ray and mammography costs—Q3 delivered the expected incremental savings from call-centre orchestration. Alongside these efficiencies, the ongoing cost-saving programme and our revised pricing structure have further improved unit economics, with RIMAB continuing disciplined portfolio management, including the active exit of sub-scale or persistently late-paying contracts, thereby strengthening profitability across the business.

The previously disclosed material deal under negotiation, has morphed into a larger opportunity but is now unlikely to be determined until Q1 FY26. While there can be no certainty the company will sign this contract, the customer continues in close contact with the company.

Political Environment Risk Update – Colombia

Debate on healthcare reform remains unresolved in the Senate, while the Government has intensified efforts (including decree-based measures and discussion of a possible referendum). Sector liquidity pressures persist intermittently amid ongoing interventions in healthcare insurance companies and payment delays to providers. IMEXHS continues to enforce tightened credit control and conservative pricing assumptions to protect cash flow and margins. Our contingency strategy has been effective, enabling us to keep working capital protected and liquidity stable.

Product and Software Updates during Q3 FY25

Progress continued during the quarter across the IMEXHS Cloud and Enterprise portfolio. Focus areas were:

- a) ongoing rollout of major features and module expansions in the new RIS (Aquila+)
- b) user-experience enhancements to the Patient Portal and Universal Viewer, and
- c) improvements to the DICOM Gateway and PACS products.

Product Update – Aquila+

Aquila+ is now production-ready across teleradiology providers, ambulatory clinics, and multi-site hospital networks, delivering measurable gains in speed, reliability, and total cost-to-serve.

For teleradiology providers, worklists load ~40% faster with fewer clicks per case. Studies are routed to the appropriate radiologist, while embedded voice recognition and an AI assistant for translation, evidence look-ups and templated reports reduce time-to-report and rework.

For ambulatory clinics and mid-size hospitals, Aquila+ provides an end-to-end RIS workflow from scheduling through to report delivery, with ready-to-use integrations for AI triage, advanced visualisation, HL7/APIs and VNA. Sites adopting the platform have realised operating savings, from digitisation and efficiency, of up to ~60%.



Headquarters Australia

Sydney, Australia
Level 7, 32 Martin Place, SYDNEY 2000
Email: enquiries@imexhs.com.au

Headquarters Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
Email: soporte@imexhs.com

Headquarters USA

Doral, Florida.
8200 NW 41st, Suite No. 200-42, CP 33166
admin.usa@imexhs.com

For personal use only

For hospital groups and networks, the platform brings enterprise controls and certifications (ISO 9001, 13485, 27001:2022), with centralised administration and BI dashboards to support standardisation, governance, disaster recovery and long-term archiving.

For IMEXHS, the product lowers the marginal cost to serve by ~70% per new SaaS customer through platform efficiencies, enables one-click tenant activation in under five minutes, and is multilingual and cloud-agnostic to support scalable roll-outs. Reliability has been consistent at 99.9% uptime, with first-response times under ten minutes and recovery of critical issues in under two hours.

[New RIS System \(Aquila+ Teleradiology System\)](#)

AI-assisted study prioritisation (Worklist)

Integration of AI for preliminary image analysis in the reading list. The system flags probability of findings and presents AI-generated suggestions to support triage of critical cases, improving diagnostic efficiency and decision-making. Integration has been tested in clinical environments with three AI providers.

Scheduling / agenda module

Management of study appointments by room/site, including tools to coordinate bookings. Enables assigning, cancelling, and modifying appointments to improve scheduling efficiency.

Immediate-attention module

Workflow for walk-in or urgent studies, enabling real-time registration, assignment and processing without prior appointments, reducing patient wait times and improving responsiveness.

Bulk report download

Export of study reports that match user-defined filters (e.g., date range, modality) to streamline document management in high-volume environments.

CRUD modules: Create/Read/Update/Delete modules for Studies, Referring Physicians and Patients. Supports controlled updates by authorised users while preserving clinical integrity, auditability and a unified patient history.

UI analytics and NPS instrumentation: Implementation of Hotjar for behaviour analytics (heatmaps, session recordings) and feedback (including NPS) to identify UX improvements and inform roadmap prioritisation.

[Patient Portal](#)

Version 3.3.2 release

Minor improvements and new features. Based on NPS feedback, changes were implemented to help patients more clearly identify the status of their results and the source of delays (often related to third-party processes), improving perceived deliverability.

[Universal Viewer](#)

MPR/MIP integration

Multiplanar Reconstruction and Maximum Intensity Projection implemented to strengthen diagnostic capability and add immediate end-user value.



Headquarters Australia

Sydney, Australia
Level 7, 32 Martin Place, SYDNEY 2000
Email: enquiries@imexhs.com.au

Headquarters Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
Email: soporte@imexhs.com

Headquarters USA

Doral, Florida.
8200 NW 41st, Suite No. 200-42. CP 33166
admin.usa@imexhs.com

New AI image assistant

Ability to upload an image to the radiologist's AI assistant to generate a draft report.

General improvements

Cornerstone tools updated and a refreshed Viewer UI implemented, advancing modernisation and usability.

[DICOM Gateway](#)

MWL enhancements

Unified installer for Gateway and MWL to simplify implementation and improve monitoring. The Cloud Gateway Admin Console is integrated with the DICOM/MWL Gateway to enable centralised monitoring and management from the cloud, providing real-time visibility, faster issue resolution and more efficient multi-site support.

[PACS](#)

Observability and DevOps

Improved log monitoring and operational controls increase reliability and maintainability. Automation supports seamless upgrades for customers migrating from PACS v2.0 to v5.0.

[Listing Rule 4.7C3](#)

In Item 6 of the Appendix 4C cash flow report for the quarter, cash payments to Related Parties of \$42,000 comprises of remuneration to an executive director.

Authorised for release by the Board of IMEXHS Limited.

-ENDS

For more information, please contact:

Business Inquiries

[Reena Minhas, CFO & Company Secretary](#)

E: enquiries@imexhs.com.au

T: +61 (0)438 481 139

About IMEXHS

IMEXHS Limited (ASX: IME) is an innovative provider of medical imaging software and radiology services in 18 countries including Colombia, the US and Australia. Founded in 2012, IMEXHS develops software as a service (SaaS) imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are completely cloud-based, vendor neutral and zero footprint, with no need for installed software. The IMEXHS products are designed to increase productivity and save money for end users, with a scalable platform that enhances patient outcomes. For more information, [visit www.imexhs.com](http://www.imexhs.com)



Headquarters Australia

Sydney, Australia
Level 7, 32 Martin Place, SYDNEY 2000
Email: enquiries@imexhs.com.au

Headquarters Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
Email: soporte@imexhs.com

Headquarters USA

Doral, Florida.
8200 NW 41st, Suite No. 200-42, CP 33166
admin.usa@imexhs.com

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity			
IMEXHS LIMITED			
ABN	Quarter ended ("current quarter")		
60 096 687 839	30 Sept 2025		
Consolidated statement of cash flows		Current quarter	Year to date (9 months)
		\$A'000	\$A'000
1	Cash flows from operating activities		
1.1	Receipts from customers	7,935	18,998
1.2	Payments for		
	(a) research and development	(354)	(955)
	(b) product manufacturing and operating costs	(2,596)	(7,135)
	(c) advertising and marketing	(56)	(105)
	(d) leased assets	(49)	(124)
	(e) staff costs	(2,317)	(7,785)
	(f) administration and corporate costs	(349)	(1,528)
1.3	Dividends received	-	-
1.4	Interest received	2	3
1.5	Interest and other costs of finance paid	(47)	(148)
1.6	Income taxes paid / received	(260)	(539)
1.7	Government grants and tax incentives	-	-
1.8	Other - indirect taxes	(736)	(980)
1.9	Net cash from / (used in) operating activities	1,173	(298)
2	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(12)	(88)
	(d) investments	-	-
	(e) intellectual property	(179)	(554)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(191)	(642)

For personal use only

3	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	2,598
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(190)
3.5	Proceeds from borrowings	-	571
3.6	Repayment of borrowings	(443)	(1,164)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	(4)	(8)
3.10	Net cash from / (used in) financing activities	(447)	1,807

4	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,495	2,072
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,173	(299)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(191)	(641)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(447)	1,805
4.5	Effect of movement in exchange rates on cash held	17	110
	Other (provide details if material)	-	-
4.6	Cash and cash equivalents at end of period	3,047	3,047

5	Reconciliation of cash and cash equivalents	Current quarter	Previous quarter
	at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	\$A'000	\$A'000
5.1	Bank balances	3,047	2,495
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,047	2,495

6	Payments to related parties of the entity and their associates	Current quarter
		\$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	42
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
	Note: payments received from related parties and their associates included in item 1 amounts to:	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

For personal use only

Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

Total facility amount at quarter end	Amount drawn at quarter end
\$A'000	\$A'000
729	729
-	-
291	291
1,020	1,020
	-

- 7.1 Loan facilities
- 7.2 Credit standby arrangements
- 7.3 Other (revolving credit facility)
- 7.4 **Total financing facilities**
- 7.5 **Unused financing facilities available at quarter end**
- 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Lender	Interest Rate	Maturity Date	Total facility	Amount drawn
<u>Unsecured</u>				
BANCO DAVIVIENDA	15.8	Nov-25	56	56
BCO BOGOTA	12.2	Feb-26	131	131
BANCO ITAU	8.8	Mar-26	144	144
BANCO ITAU	8.8	Dec-26	120	120
BCO ITAU	12.5	Dec-26	240	240
BCO BOGOTA	15.0	Jul-27	38	38
JEEVES	21.6	Revolving (monthly)	273	273
BBVA	21.6	Revolving (monthly)	18	18

Weighted average interest rate of 15.4% on borrowings.

	\$A'000
8 Estimated cash available for future operating activities	
8.1 Net cash from / (used in) operating activities (item 1.9)	1,173
8.2 Cash and cash equivalents at quarter end (item 4.6)	3,047
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	3,047
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

- 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:
 - 8.6 1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
N/A
 - 8.6 2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

N/A
 - 8.6 3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2025

Authorised by: The Board of IMEXHS LIMITED

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the *[name of board committee – eg Audit and Risk Committee]*". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.